

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/635,797 Confirmation No.: 2719
Applicant: Rapin, *et al.*
Filed: August 5, 2003
TC/AU.: 1614
Examiner: Unassigned

Docket No.: NEURO 101
Customer No.: 20786
Title: Tripeptides and Tripeptide Derivatives for the Treatment of Neurodegenerative Diseases

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT


Sir:

The citation of information on the attached Form PTO-1449, "List of Art Cited by Applicant" is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each reference is enclosed. The Examiner's attention is drawn to the following co-pending applications: U.S.S.N. 10/635,696; U.S.S.N. 10/635,797; and U.S.S.N. 10/635,805.

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

This Information Disclosure Statement is filed before receipt of a first Office action on the merits of this application, thus no fee payment as set forth under § 1.17(p) is enclosed. If any other fee is due, please charge any fees or credit any overpayment to Deposit Account No. 11-0980.


Respectfully submitted,


Madeline I. Johnston
Reg. No. 36,174

King & Spalding, LLP
191 Peachtree Street, N.E., Atlanta, GA 30303
Office: (404)572-4600/ Fax: 404-572-5145

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on November 25, 2003.


Tisha Hardick

The U.S.P.T.O. official mailroom stamp affixed hereto acknowledges receipt of the items listed below.

Applicant

Rapin, *et al.*

Serial No.

10/635,797

Title

Tripeptides and Tripeptide Derivatives for the Treatment of Neurodegenerative Diseases

Papers Submitted:

Information Disclosure Statement (1 p.); Form 1449A PTO Forms (3 pages); 39 references

Attorney

Madeline I. Johnston, Esq.

Date Mailed

November 25, 2003

Docket

Neuro 101

First Class Mail

HASLER


\$0.23

US POSTAGE

POSTCARD

MAILED FROM 30303

011A0413000397



KING & SPALDING
191 PEACHTREE STREET
ATLANTA, GEORGIA 30303-1763

ATTENTION:

Tisha Hardwick, 45th Floor

Please type a plus sign (+) inside this box

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				Complete if Known	
				Application Number	10/635,797
				Filing Date	August 5, 2003
				First Named Inventor	Rapin, et al.
				Group Art Unit	1614
				Examiner Name	Unassigned
Sheet	1	of	3	Attorney Docket Number	NEURO 101

3354579_1

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
AA		5,212,158	A	VANDAI	05-18-1993
AB		5,973,111	A	BEMIS, et al.	10-26-1999
AC		6,156,572	A	BELLAMKONDA, et al.	12-05-2000
AD		6,235,929	B1	POWERS	05-22-2001

FOREIGN PATENT DOCUMENTS								
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code ² (if known)				
✓ AE	EP	0,316,218	A1		INORGAN, S.A.	05-17-1989		
✓ AF	EP	1,018,341	A		CALPIS Co., Ltd.	07-12-2000		
✓ AG	EP	1,231,279	A1		CALPIS Co., Ltd.	08-14-2002		
✓ AH	EP	0,446,706	A2, A3		MERCK PATENT GESELLSCHAFT	09-18-1991		
✓ AI	JP	04-005240 w/ PAJ abstract	A		TAISHO PHARMACEUT. Co.;	01-09-1992		
✓ AJ	WO	88/09604	A2		MEDICIS Corp.	12-15-1988		
✓ AK	WO	92/11850	A2		CORTEX PHARMA; GA. TECH. RES. INST.	07-23-1992		
✓ AL	WO	96/41638	A1		SANOFI WINTHROP	12-27-1996		
✓ AM	WO	98/14202	A1		AUCKLAND UNISERVICES, Ltd.	04-09-1998		
✓ AN	WO	01/28578	A2, A3		WRAIR	04-26-2001		
✓ AO	WO	01/34828	A1		CALPIS Co. Ltd.	05-17-2001		
✓ AP	WO	01/68114	A1		MONSANTO Co. (US)	09-20-2001		
✓ AQ	WO	02/062373	A2,A3		TELL PHARM. AG	08-15-2002		
✓ AR	WO	02/062828	A2,A3		TELL PHARM. AG	08-15-2002		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

→

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
Sheet	2	of	3	Application Number	10/635,797
				Filing Date	August 5, 2003
				First Named Inventor	Rapin, et al.
				Group Art Unit	1614
				Examiner Name	Unassigned
				Attorney Docket Number	NEURO 101

3354579_1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	BA	BEYER, H., and WALTER, W., <i>Handbook of Organic Chemistry</i> , by S. Hirzel Verlag, Stuttgart (English translation of the 22 nd edition of <i>Lehrbuch der Organischen Chemie</i>) (1996), pp. 827-838.
	BB	BLUNDELL, T.L., et al., "Knowledge-based protein modelling and design", <i>Eur. J. Biochem.</i> , 172:513-520 (1988).
	BC	CHESSEBEUF, M., et al., "Rat liver epithelial cell cultures in a serum-free medium: primary cultures and derived cell lines expressing differentiated functions", <i>In Vitro</i> , 20(10):780-795 (1984).
	BD	CLARK, M.C., et al., "Validation of the general purpose Tripos 5.2 force field", <i>J. Comp. Chem.</i> , 10(8):982-1012 (1999).
	BE	DE POOTER, H., et al., "N-acylamino acids and peptides IV the synthesis of N-cinnamyl-, N-p.coumaryl- and N-caffeyl-glycine and -glycyl-L-phenylalanine", <i>Bull. Soc. Chim. Belg.</i> , 85(9):647-656 (1976). XP008015013.
	BF	FADEN, A.I., et al., "Novel TRH analog improves motor and cognitive recovery after traumatic brain injury in rodents", <i>Amer. J. Physiology</i> 277(4, pt. 2):R1196-R1204 (1999), <i>Chem. Abstr.</i> 132:31033 XP002207513, XP008014976.
	BG	FADEN, A.I., et al., "Structure-activity relationships of TRH analogs in rat spinal cord injury", <i>Brain Research</i> , 448:287-293 (1988). XP008015202.
	BH	GASTEIGER, J., et al., "Iterative partial equalization of orbital electronegativity -- a rapid access to atomic charges", <i>Tetrahedron</i> , 36:3219-3238 (1980).
	BI	HAGG, T., et al., "Delayed treatment with nerve growth factor reverses the apparent loss of cholinergic neurons after acute brain damage", <i>Exp. Neurol.</i> , 101:303-312 (1988).
	BJ	JONES, D.T., et al., "A new approach to protein fold recognition", <i>Nature</i> , 358:86-89 (July 1992).
	BK	JONES, D.T., "Protein secondary structure prediction based on position-specific scoring matrices", <i>J. Mol. Biol.</i> , 292(2):195-202 (1999).
	BL	KANSY, M., et al. "Physicochemical High Throughput Screening: Parallel Artificial Membrane Permeation Assay in the Description of Passive Absorption Processes", <i>J. Med. Chem.</i> , 41(7):1007-1010 (March 26, 1998).

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	3	of	3	Application Number	10/635,797
				Filing Date	August 5, 2003
				First Named Inventor	Rapin, et al.
				Group Art Unit	1614
				Examiner Name	Unassigned
				Attorney Docket Number	NEURO 101

3354579_1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	BM	KHUEBACHOVA, M., et al., "Mapping the C terminal epitope of the Alzheimer's disease specific antibody MN423", <i>J. Immunol. Methods</i> (Elsevier Amsterdam, NL) 262(1-2):205-215 (2002). XP004352190.		T ⁶
	CA	LASKOWSKI, R.A., et al., "PROCHECK: a program to check the stereochemical quality of protein structures", <i>J. Appl. Cryst.</i> , 26:283-291 (1993).		
	CB	LE PONCIN-LAFITTE, M., et al., "Sound-avoidance conditioning and a mathematical approach to the description of acquisition performance", <i>Math. Biosciences</i> , 59:249-268 (1982).		
	CC	LUCO, J.M., "Prediction of the brain-blood distribution of a large set of drugs from structurally derived descriptors using partial least-squares (PLS) modeling", <i>J. Chem.. Inf. Comput. Sci.</i> , 39 (2):396-404 (1999)		
	CD	PARNETTI, L., et al., "Posatirelin for the treatment of late-onset Alzheimer's disease: a double-blind multicentre study vs citalopram and ascorbic acid", <i>Acta Neurol. Scand.</i> 92:135-140 (1995).		
	CE	VARON, S., et al., "Nerve Growth Factor in CNS Repair", <i>J. Neurotrauma</i> , 11(5) (1994)		
	CF	WANG, R., et al., "SCORE: A new empirical method for estimating the binding affinity of a protein-ligand complex", <i>J. Mol. Model.</i> , 4:379-394 (1998).		
	CG	WEINER, S.J., et al., "A new force field for molecular mechanical simulation of nucleic acids and proteins", <i>J. Am. Chem. Soc.</i> , 106:765-784 (1984)		
	CH	WIESMAN, C., et al., "Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor", <i>Nature</i> , 401:184 (September 9, 1999).		

3354579_1

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.